Hormonal
In patients with type 2 diabetes, subcutaneous semaglutide produces superior long-term weight loss compared to oral semaglutide over a two-year period.
If you have Type 2 Diabetes and are using semaglutide for weight loss, the injection form is significantly more effective than the pill form over the long term (2 years). You will likely lose more weight and have a higher chance of losing 10% or more of your body weight with the injection. However, if you are over 65, the oral pill might offer weight loss results similar to the injection, making it a viable alternative if you want to avoid needles.
Subcutaneous users achieved superior weight loss compared to oral users.
Why this rating
Real-world retrospective cohort study with a relatively small sample size for the oral group (n=57).
Source
Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database
Jimmy Kwon et al. · Expert Review of Endocrinology & Metabolism · 2025
DOI 10.1080/17446651.2025.2462100
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →